Study Finds Weight‑loss Injections Associated With Large Drop in Hospital Admissions and Death Among Heart Failure Patients
Analysis of more than 90,000 patients with obesity, type 2 diabetes and HFpEF links semaglutide use to up to a 58% lower risk of death or hospitalization, though researchers urge randomized trials to confirm benefits.